Abstracts tagged "patient outcomes"

Abstract Number: 2577 • 2018 ACR/ARHP Annual Meeting
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
Anthony Turkiewicz¹, Amanda M. Gellett², Lisa Kerr², Julie Birt² and Jordi Gratacos³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain
Background/Purpose: PsA is a chronic and complex inflammatory disease with both articular and extra-articular symptoms, including joint pain, enthesitis, dactylitis, fatigue, and skin and nail…
Abstract Number: 326 • 2018 ACR/ARHP Annual Meeting
Implementation of a Treat-to-Target Quality Improvement Program for Rheumatoid Arthritis Management Using Real-Time Patient Reported Outcome Measures
Malka Forman¹, Cianna Leatherwood², Chang Xu¹, Eunji Ko¹, Bing Lu³, Maura D. Iversen⁴, Daniel Solomon² and Sonali Desai², ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Changing clinical practice patterns and incorporation patient-reported outcome measures (PROMs) for disease activity assessment into routine workflow is challenging. We sought to integrate a…
Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu², Meghan Glynn², Kelechi Emeanuru², Leslie R Harrold³, Sven Richter⁴, Benoit Guerette⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celgene Corporation, Summit, NJ, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
Abstract Number: 408 • 2018 ACR/ARHP Annual Meeting
State or Trait: Pain Catastrophizing and Widespread Pain Following TKR and Their Associations with Pain Relief
Emma Lape¹, Faith Selzer^1,2, Jamie E. Collins^3,4, Elena Losina^1,4 and Jeffrey N. Katz^1,4, ¹Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Department of Orthopedic Surgery, Harvard Medical School, Boston, MA, ³Department of Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, MA
Background/Purpose: Pain catastrophizing and widespread pain (WP) —constructs reflecting cognitive processes during the pain experience—predict disability, pain chronicity/severity, and lower quality of life in a…
Abstract Number: 2910 • 2018 ACR/ARHP Annual Meeting
Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials
Liana Fraenkel¹, W. Benjamin Nowell², Carole Wiedmeyer², Zhenglin Wei³, Kaleb Michaud⁴, Tuhina Neogi⁵, Christine Ramsey¹ and David Broniatowski³, ¹Yale University School of Medicine, New Haven, CT, ²Global Healthy Living Foundation, Upper Nyack, NY, ³George Washington University, Washington, DC, ⁴Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Randomized controlled trials currently report benefits and adverse events (AEs) separately, and therefore do not permit comparisons of patients’ overall experiences on one treatment…
Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting
Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE
Anne C. Bay-Jensen¹, Christian S. Thudium¹, Claus Christiansen² and Morten A. Karsdal¹, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting
Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients
Jens Gert Kuipers¹, Michael Koller², Ulrich Rueffer³, Florian Zeman², Karolina Mueller⁴ and Joachim Weis⁵, ¹Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³German Fatigue Society, Cologne, Germany, ⁴Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁵University Clinic Centre Freiburg, Freiburg, Germany
Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
Abstract Number: 1391 • 2018 ACR/ARHP Annual Meeting
Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice
Rubén Queiro¹, Juan Cañete², Carlos Alberto Montilla-Morales³ and Miguel A. Abad⁴, ¹Rheumatology Division, HUCA, Oviedo, Spain, ²Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ⁴FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are remission or low disease activity. We know little about whether these objectives correlate well with a patient-acceptable…
Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Stanley Cohen¹, Ahmed Samad², Elaine Karis², Bradley S. Stolshek², Mona Trivedi², Hao Zhang², Girish A. Aras², Greg Kricorian² and James Chung², ¹Metroplex Clinical Research Center, Dallas, TX, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…
Abstract Number: 1407 • 2018 ACR/ARHP Annual Meeting
Differences in the Measurement Properties of the Patient-Reported Outcomes Measurement Information System Physical Function Short-Form 10a Among Racial/Ethnic Minorities with Rheumatoid Arthritis
Zara Izadi¹, Patricia Katz², Gabriela Schmajuk³, Julie Gandrup⁴, Jing Li⁵, Milena Gianfrancesco⁶ and Jinoos Yazdany⁷, ¹Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ⁴Rheumatology, Odense University Hospital, Odense, Denmark, ⁵Medicine, UC San Francisco, San Francisco, CA, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Most studies evaluating patient-reported outcomes such as the PROMIS Physical Function Short Form 10a (PF10a) in rheumatoid arthritis (RA) have been performed in white…
Abstract Number: 1602 • 2018 ACR/ARHP Annual Meeting
Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Winnie Hua², Robert R. McLean², Peter Hur⁴ and Alexis Ogdie⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies showed psoriatic arthritis (PsA) patients with enthesitis had greater disease burden than patients without enthesitis, yet it is unknown whether the impact…
Abstract Number: 2030 • 2017 ACR/ARHP Annual Meeting
Patient Motivation in Inflammatory Arthritis: The Use of Ultrasound-Guided Patient Education to Endorse Medication Adherence and Facilitate Cost-Effective Targeted Management
Yasser M. El Miedany^1,2, Maha El Gaafary³, Nadia El Aroussy¹, Sally Youssef⁴ and Deborah Palmer⁵, ¹Rheumatology and Rehabilitation, Ain Shams University, Cairo, Egypt, ²Rheumatology, Darent Valley Hospital, Dartford, United Kingdom, ³Community, Environmental and Occupational Medicine, Ain Shams University, Abbassia, Egypt, ⁴Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt, ⁵Rheumatology, North Middlesex University Hospital, London, United Kingdom
Background/Purpose: To assess the value of sharing the real-time ultrasound (US) images of the inflamed joints/ tendons with inflammatory arthritis patients and its impact on:…
Abstract Number: 2252 • 2017 ACR/ARHP Annual Meeting
Initial Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) in Children with Juvenile Myositis
Kaveh Ardalan^1,2, David Cella³, Lauren M. Pachman⁴, Elizabeth L. Gray⁵, Julia (Jungwha) Lee⁵, Kyle Fahey^6,7, Madison Wolfe^6,7, Megan L. Curran^7,8, Mariana C. Marques^6,7 and Rowland W. Chang⁹, ¹Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Division of Rheumatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Preventive Medicine, Medicine, and Physical Medicine & Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Juvenile myositis (JM) can worsen quality of life (QoL) via proximal weakness, rashes, and treatments side effects. QoL legacy instruments may be limited by…
Abstract Number: 2254 • 2017 ACR/ARHP Annual Meeting
Disability (HAQ) and Quality of Life (SF-12) As Related to Adherence and Health Literacyin Patients with Rheumatoid Arthritis – the Trace-Study
Jens Gert Kuipers¹, Michael Koller², Florian Zeman², Karolina Mueller² and Jens Ulrich Rueffer³, ¹Department of Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²University Hospital Regensburg, Center for Clinical Studies, Regensburg, Germany, ³German Fatigue Society, Cologne, Germany
Background/Purpose: Disabilities in daily living and quality of life are key endpoints to evaluate the outcome of treatment for rheumatoid arthritis (RA). Among factors that…
Abstract Number: 2261 • 2017 ACR/ARHP Annual Meeting
Supporting Smoking Cessation in RA and SLE: Identifying Patient-Centered Outcomes
Aimée Wattiaux¹, Laura Block², Andrea Gilmore-Bykovskyi², Edmond Ramly³, Jane Sadusky⁴, Megan Piper⁵, Brittany Bettendorf⁶, Ann Rosenthal⁷ and Christie M. Bartels⁸, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Nursing, Madison, WI, ³Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ⁴Research Consultant, Madison, WI, ⁵University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, ⁶Rheumatology, Medical College of Wisconsin, MIlwaukee, WI, ⁷Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁸Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Patients with RA and SLE are at higher risk for premature cardiovascular disease (CVD) than peers. Smoking is a leading modifiable risk factor for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].